[go: up one dir, main page]

LU91725B1 - Novel uses of V-ATPASE inhibitors - Google Patents

Novel uses of V-ATPASE inhibitors

Info

Publication number
LU91725B1
LU91725B1 LU91725A LU91725A LU91725B1 LU 91725 B1 LU91725 B1 LU 91725B1 LU 91725 A LU91725 A LU 91725A LU 91725 A LU91725 A LU 91725A LU 91725 B1 LU91725 B1 LU 91725B1
Authority
LU
Luxembourg
Prior art keywords
atpase inhibitors
novel uses
novel
atpase
inhibitors
Prior art date
Application number
LU91725A
Inventor
Claude Muller
Konstantin Mueller
Original Assignee
Ct De Rech Public De La Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Rech Public De La Sante filed Critical Ct De Rech Public De La Sante
Priority to LU91725A priority Critical patent/LU91725B1/en
Priority to PCT/EP2011/065235 priority patent/WO2012028732A1/en
Application granted granted Critical
Publication of LU91725B1 publication Critical patent/LU91725B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU91725A 2010-09-02 2010-09-02 Novel uses of V-ATPASE inhibitors LU91725B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LU91725A LU91725B1 (en) 2010-09-02 2010-09-02 Novel uses of V-ATPASE inhibitors
PCT/EP2011/065235 WO2012028732A1 (en) 2010-09-02 2011-09-02 Novel uses of v-atpase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU91725A LU91725B1 (en) 2010-09-02 2010-09-02 Novel uses of V-ATPASE inhibitors

Publications (1)

Publication Number Publication Date
LU91725B1 true LU91725B1 (en) 2012-03-05

Family

ID=43759675

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91725A LU91725B1 (en) 2010-09-02 2010-09-02 Novel uses of V-ATPASE inhibitors

Country Status (2)

Country Link
LU (1) LU91725B1 (en)
WO (1) WO2012028732A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171672A1 (en) * 2000-08-04 2004-09-02 De Brabander Jef Karel Synthetic salicylihalamides, apicularens and derivatives thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981525A (en) 1995-01-10 1999-11-09 Smithkline Beecham Corporation Indole derivatives useful in the treatment of osteoporosis
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US7381744B1 (en) 1999-03-05 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171672A1 (en) * 2000-08-04 2004-09-02 De Brabander Jef Karel Synthetic salicylihalamides, apicularens and derivatives thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BOYD M R ET AL: "Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS APR 2001 LNKD- PUBMED:11259534, vol. 297, no. 1, April 2001 (2001-04-01), pages 114 - 120, XP002630459, ISSN: 0022-3565 *
GONG JIANZHI ET AL: "Potential Targets and Their Relevant Inhibitors in Anti-influenza Fields", CURRENT MEDICINAL CHEMISTRY, vol. 16, no. 28, October 2009 (2009-10-01), pages 3716 - 3739, XP002630456, ISSN: 0929-8673 *
HUSS MARKUS ET AL: "Inhibitors of V-ATPases: old and new players", JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 212, no. 3, February 2009 (2009-02-01), pages 341 - 346, XP002630458, ISSN: 0022-0949 *
KH MÜLLER: "The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections", BRITISH JOURNAL OF PHARMACOLOGY, 1 January 2011 (2011-01-01), XP009146609 *
KUNZE ET AL: "Cruentaren A, a highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 18, 19 July 2007 (2007-07-19), pages 3523 - 3527, XP022191426, ISSN: 0014-5793, DOI: DOI:10.1016/J.FEBSLET.2007.06.069 *
LEBRETON S ET AL: "Ring-closing metathesis: a powerful tool for the synthesis of simplified salicylihalamide-based V-ATPase inhibitors", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 60, no. 43, 18 October 2004 (2004-10-18), pages 9635 - 9647, XP004573961, ISSN: 0040-4020, DOI: DOI:10.1016/J.TET.2004.06.146 *
WU Y ET AL: "Total synthesis and initial structure - Function analysis of the potent V-ATPase inhibitors salicylihalamide A and related compounds", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 20020403 US LNKD- DOI:10.1021/JA0177713, vol. 124, no. 13, 3 April 2002 (2002-04-03), pages 3245 - 3253, XP002630461, ISSN: 0002-7863 *
XIE X -S ET AL: "Salicylihalamide A Inhibits the Vo Sector of the V-ATPase through a Mechanism Distinct from Bafilomycin A1", JOURNAL OF BIOLOGICAL CHEMISTRY 20040507 US LNKD- DOI:10.1074/JBC.M313796200, vol. 279, no. 19, 7 May 2004 (2004-05-07), pages 19755 - 19763, XP002630460, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2012028732A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
ZA201206456B (en) Uses of dgati inhibitors
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
IL222713A0 (en) Method of reducing biofilms
ZA201206424B (en) Inhibitors of semicarabazide-sensitive amine oxidase
EP2576552A4 (en) Benzoquinolone inhibitors of vmat2
GB201003274D0 (en) Methods of connecting
GB201004179D0 (en) Enzyme inhibitors
GB201004178D0 (en) Enzyme inhibitors
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
SG11201400102WA (en) Inhibitors of nedd8-activating enzyme
SG10201404913QA (en) Inhibitors of cognitive decline
IL217833A0 (en) Inhibitors of cognitive decline
SI2506840T1 (en) Uses of hypoxia-inducible factor inhibitors
EP2635287A4 (en) Administration of nedd8-activating enzyme inhibitor
IL222474A0 (en) Method of synthesis
EP2591368A4 (en) Methods for determination of ethanol consumption
GB2492717B (en) Detecting no progress state of an application
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
HK1176856A (en) Uses of dgat1 inhibitors
HK1192727A (en) Combination of kanase inhibitors and uses thereof
GB0908609D0 (en) New use of isoQC inhibitors
GB201003502D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors